Connect Biopharma Holdings LtdConnect Biopharma Holdings Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

If you are employed by Connect Biopharma Holdings Ltd and you wish to licence your Sustainability aseessment, please contact us. This page contains a zero-cost Environmental, Social and Governance report covering Connect Biopharma Holdings Ltd. This webpage contains a Q&A table on Connect Biopharma Holdings Ltd.

Connect Biopharma Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 1.6, social score of 4.8 and governance score of 2.7.

SDG Transparency Score for Connect Biopharma Holdings Ltd 

3.0

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Connect Biopharma Holdings Ltd 
1.6

Environmental

4.8

Social

2.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1760Protagenic Therapeutics Inc
3.1
Medium
1760Vcanbio Cell & Gene Engineering Corp Ltd
3.1
Medium
1800Connect Biopharma Holdings Ltd
3.0
Medium
1800Allergan plc
3.0
Medium
1800Aptevo Therapeutics Inc
3.0
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Connect Biopharma Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd offer flexible work?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose water use targets?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Connect Biopharma Holdings Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Connect Biopharma Holdings Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Connect Biopharma Holdings Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose its waste policy?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose energy use targets?

LockedSign up for free to unlock

Does Connect Biopharma Holdings Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Connect Biopharma Holdings Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Connect Biopharma Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Sorry!

Failed to process!